News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
<IPO>IMPACT THERAP-B's Max. HKD910M IPO Starts Tdy With Entry Fee HKD4,394
IMPACT THERAP-B (07630.HK), a biotechnology company at the commercialization stage, kicked off its IPO today (5th), which will last until this Friday (8th).The company plans to iss...
Reset
Send
The window will close in 5 seconds
<IPO>IMPACT THERAP-B's Max. HKD910M IPO Starts Tdy With Entry Fee HKD4,394
Close
Recommend
28
Positive
26
Negative
25
 
 

IMPACT THERAP-B (07630.HK), a biotechnology company at the commercialization stage, kicked off its IPO today (5th), which will last until this Friday (8th).

The company plans to issue 41.977 million H-shares, with 10% allocated to the Hong Kong public offering. With an offer price of HKD19.75-21.75 per share, this IPO aims to raise up to HKD910 million. The entry fee for a board lot of 200 shares is HKD4,393.9. The listing is scheduled for May 13.

Related News HSBC Research Cites Experts: TENCENT (00700.HK) and BABA-W (09988.HK) Benefit from Ecosystem Advantages
IMPACT THERAP-B has introduced a group of cornerstone investors, including TENCENT (00700.HK)  +5.400 (+1.181%)    Short selling $1.73B; Ratio 14.111%   , LAV, and WWHCP. They have subscribed for USD35.74 million worth of shares.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.)

Auto-translated by AI
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.